TP53
circulating cell-free DNA
circulating tumor DNA
deep sequencing
esophageal squamous cell carcinoma
liquid biopsy
neoantigen
tumor mutation
variant caller
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
07
04
2021
revised:
28
04
2021
accepted:
17
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Circulating cell-free DNA (cfDNA) is emerging as a potential tumor biomarker. CfDNA-based biomarkers may be applicable in tumors without an available non-invasive screening method among at-risk populations. Esophageal squamous cell carcinoma (ESCC) and residents of the Asian cancer belt are examples of those malignancies and populations. Previous epidemiological studies using cfDNA have pointed to the need for high volumes of good quality plasma (i.e., >1 mL plasma with 0 or 1 cycles of freeze-thaw) rather than archival serum, which is often the main available source of cfDNA in retrospective studies. Here, we have investigated the concordance of
Identifiants
pubmed: 34073316
pii: ijms22115627
doi: 10.3390/ijms22115627
pmc: PMC8197963
pii:
doi:
Substances chimiques
Circulating Tumor DNA
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute for Medical Research Development
ID : 977009
Organisme : CRUK grand challenge
ID : JVA31108425-1
Références
Int J Mol Sci. 2020 Nov 16;21(22):
pubmed: 33207777
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817150
Nat Commun. 2017 Sep 12;8(1):524
pubmed: 28900112
BMJ. 2009 Mar 26;338:b929
pubmed: 19325180
Dig Surg. 2013;30(4-6):331-6
pubmed: 24051550
Cancers (Basel). 2020 Oct 21;12(10):
pubmed: 33096708
J Am Acad Dermatol. 2020 Sep;83(3):709-717
pubmed: 32387665
Biometrics. 2014 Dec;70(4):920-31
pubmed: 25156188
Oncotarget. 2017 Aug 7;8(42):72621-72632
pubmed: 29069814
NAR Genom Bioinform. 2020 Jun;2(2):lqaa021
pubmed: 32363341
Int J Mol Sci. 2020 Oct 29;21(21):
pubmed: 33137955
BMC Med. 2018 Oct 2;16(1):166
pubmed: 30285732
Blood Adv. 2019 Mar 12;3(5):724-728
pubmed: 30814057
Clin Chem. 2020 Jul 1;66(7):946-957
pubmed: 32516802
Science. 2018 Nov 23;362(6417):911-917
pubmed: 30337457
Gastroenterology. 2020 Feb;158(3):494-505.e6
pubmed: 31711920
Oncotarget. 2016 Sep 20;7(38):62280-62291
pubmed: 27556701
PLoS One. 2011;6(12):e29488
pubmed: 22216294
Eur J Haematol. 2017 Oct;99(4):291-299
pubmed: 28692178
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Cell Rep. 2014 Jun 12;7(5):1649-1663
pubmed: 24835989
Cancers (Basel). 2020 Oct 02;12(10):
pubmed: 33023117
PLoS One. 2016 Aug 04;11(8):e0160519
pubmed: 27490490
R Soc Open Sci. 2017 Apr 5;4(4):170050
pubmed: 28484631
Br J Cancer. 2014 Dec 9;111(12):2235-41
pubmed: 25247319
Mutat Res. 2007 May-Jun;635(2-3):105-117
pubmed: 17257890
Clin Biochem. 2016 Dec;49(18):1379-1386
pubmed: 27620950
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Exp Hematol. 2020 Mar;83:66-73
pubmed: 31893524
ACS Omega. 2020 Oct 12;5(41):26402-26412
pubmed: 33110968
EBioMedicine. 2016 Aug;10:117-23
pubmed: 27377626
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):582-597
pubmed: 32246941
Nucleic Acids Res. 2019 Jan 8;47(D1):D163-D169
pubmed: 30335176
Clin Chem. 2018 Nov;64(11):1626-1635
pubmed: 30150316
Hum Mutat. 2016 Sep;37(9):865-76
pubmed: 27328919
N Engl J Med. 2019 Jan 10;380(2):152-162
pubmed: 30625052